1. Steinbichler TB, Dudas J, Ingruber J, Glueckert R, Sprung S, Fleischer F, Cidlinsky N, Dejaco D, Kofler B, Giotakis AI, Skvortsova II, Riechelmann H. Slug Is A Surrogate Marker of Epithelial to Mesenchymal Transition (EMT) in Head and Neck Cancer. J Clin Med. 2020 Jun 30;9(7):2061.
  2. Skvortsova II, Span PN. Editorial: Advances in Biological Understanding of Tumor Radiation Resistance. Front Oncol. 2020 May 12;10:754. doi: 10.3389/fonc.2020.00754. eCollection 2020.PMID: 32477955 
  3. Arnold CR, Mangesius J, Skvortsova II, Ganswindt U. The Role of Cancer Stem Cells in Radiation Resistance. Front Oncol. 2020 Feb 20;10:164. doi: 10.3389/fonc.2020.00164.
  4. Negro G, Aschenbrenner B, Brezar SK, Cemazar M, Coer A, Gasljevic G, Savic D, Sorokin M, Buzdin A, Callari M, Kvitsaridze I, Jewett A, Vasileva-Slaveva M, Ganswindt U, Skvortsova I, Skvortsov S. Molecular heterogeneity in breast carcinoma cells with increased invasive capacities. Radiol Oncol. 2020 Feb 14;54(1):103-118.
  5. Skvortsova I. Special Issue "Enigmatic tumor properties associated with metastatic spread" seminars in cancer biology,  Semin Cancer Biol. 2020 Feb;60:iii-iv. 


  1. Digomann D, Kurth I, Tyutyunnykova A, Chen O, Löck S, Gorodetska I, Peitzsch C, Skvortsova II, Negro G, Aschenbrenner B, Eisenhofer G, Richter S, Heiden S, Porrmann J, Klink B, Schwager C, Dowle AA, Hein L, Kunz-Schughart LA, Abdollahi A, Lohaus F, Krause M, Baumann M, Linge A, Dubrovska A. The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clin Cancer Res. 2019 Jan 22. doi: 10.1158/1078-0432.CCR-18-2951.
  2. Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova I. Therapy resistance mediated by exosomes. Molecular Cancer, 2019, 2019 Mar 30;18(1):58.
  3. Steinbichler TB, Savic D, Dejaco D, Romani A, Kofler B, Skvortsova II, Riechelmann H, Dudas J. Pleiotropic Effects of Epithelial Mesenchymal Crosstalk on Head and Neck Cancer: EMT and beyond. Cancer Microenviron. 2019 Jul 11.
  4. Dwivedi AR, Thakur A, Kumar V, Skvortsova I, Kumar V. Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer. Curr Drug Targets. 2019 Aug 21.
  5. Steinbichler TB, Savic D, Dudás J, Kvitsaridze I, Skvortsov S, Riechelmann H, Skvortsova II. Cancer stem cells and their unique role in metastatic spread. Semin Cancer Biol. 2019 Sep 12. pii: S1044-579X(19)30264-0.
  6. Skvortsova I. Special Issue "Enigmatic tumor properties associated with metastatic spread" Seminars in Cancer Biology, Volume XX. Semin Cancer Biol. 2019 Nov 2. pii: S1044-579X(19)30372-4.


  1. Feiersinger GE, Trattnig K, Leitner PD, Guggenberger F, Oberhuber A, Peer A, Hermann M, Skvortsova I, Vrbkova J, Bouchal J, Culig Z, Santer FR. Olaparib is effective in combination with and as maintenance therapy after first-line endocrine therapy in prostate cancer cells. Molecular Oncology 2018
  2. Callari M, Gandellini P, Skvortsova I, Span PN. Predicting and Understanding Cancer Response to Treatment. Dis Markers. 2018 May 29;2018:6159214
  3. Salgado R, Harris L, Skvortsova I, Denkert C, Loi S. In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers. Semin Cancer Biol. 2018 Oct;52(Pt 2):v-vi.
  4. Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018 Dec;53:156-167
  5. Skvortsova I. Special Issue "Cancer Stem Cells: Impact on Treatment". Semin Cancer Biol. 2018 Dec;53:iii-iv


  1. Steinbichler TB, Dudás J, Riechelmann H, Skvortsova II. The Role of Exosomes in Cancer Metastasis. Semin Cancer Biol. 2017 Feb 12.
  2. Kumar B, Singh S, Skvortsova II, Kumar V.  Promising Targets in Anti-Cancer Drug Development: Recent Updates. Curr Med Chem. 2017 Mar 31. doi: 10.2174/0929867324666170331123648
  3. Varga A, Ehrenreiter K, Aschenbrenner B, Kocieniewski P, Kochanczyk M, Lipniacki T, Baccarini M. RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα. . 2017 Mar 7;10(469).
  4. Skvortsova II. Special issue: Progress in biological understanding of cancer metastasis. Semin Cancer Biol. 2017; 44:1-2
  5. Skvortsova II, Kumar V. Editorial: Recent Trends in Anticancer Drug Development: Challenges and Opportunities. Curr Med Chem. 2017 Jan 11;24(42):4727-4728.
  6. Steinbichler TB, Abdelmoez A, Metzler MV, Dejaco D, Riechelmann H, Dudas J, Skvortsova II. Epithelial-mesenchymal crosstalk induces radioresistance in HNSCC cells. Oncotarget. 2017 Dec 14;9(3):3641-3652.
  7. Abdelmoez A, Coraça-Huber DC, Thurner GC, Debbage P, Lukas P, Skvortsov S, Skvortsova II. Screening and identification of molecular targets for cancer therapy. Cancer Lett. 2017 Feb 28;387:3-9


  1. Seppi T, Prajczer S, Dörler MM, Eiter O, Hekl D, Nevinny-Stickel M, Skvortsova I, Gstraunthaler G, Lukas P, Lechner J. Sex Differences in Renal Proximal Tubular Cell Homeostasis. J Am Soc Nephrol, 2016 Oct;27(10):3051-3062.
  2. Kumar B, Kumar R, Skvortsova II, Kumar V. Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on Their Therapeutic Potential and Clinical Trials. Curr Cancer Drug Targets. 2016 Sep 28.
  3. Skvortsova II. Introduction to the Special Issue “Cancer Stem Cells: Impact on Treatment”. J Cancer Metastasis Treat 2016;2:231-2


  1. Skvortsov S, Arnold CR, Debbage P, Lukas P. Proteomic approach to understand metastatic spread. Proteomics Clin Appl. 2015: 9(11-12):1069-1077.
  2. Ahmed B, Debbage P, Skvortsov S, Lukas P, Skvortsova I. Head and Neck Squamous Cell Carcinoma (HNSCC) Protein Profiles Associated with Tumor Response to Treatment. J Transl Proteomics Res, 2015: 2: 3-14.
  3. Skvortsova I, Debbage P, Kumar V, Skvortsov S. Radiation resistance: Cancer stem cells (CSCs) and their enigmatic pro-survival signaling. Semin Cancer Biol. 2015: 35:39-44
  4. Skvortsova I. Where are we in understanding cancer biology? Semin Cancer Biol. 2015: 35: 1-2.
  5. Skvortsova I. EDITORIAL. Semin Cancer Biol. 2015 Apr;31:1-2
  6. Skvortsov S, Debbage P, Lukas P. Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways. Semin Cancer Biol. 2015 Apr;31:36-42


  1. Skvortsov S, Debbage P, Skvortsova II. Proteomics of cancer stem cells. Int J Radiat Biol. 2014; 90(8):653-8.
  2. Skvortsov S, Debbage P, Cho WC, Lukas P, Skvortsova I. Putative biomarkers and therapeutic targets associated with radiation resistance. Exp Rev Proteomics 2014 Apr;11(2):207-14.
  3. Skvortsov S, Dudás J, Eichberger P, Witsch-Baumgartner M, Loeffler-Ragg J, Pritz C, Schartinger VH, Maier H, Hall J, Debbage P, Riechelmann H, Lukas P. Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC). Br J Cancer. 2014 May 27;110(11):2677-87.
  4. Baro M, de Llobet LI, Figueras A, Skvortsova I, Mesia R, Balart J. 2014 Sep 23;111(7):1310-8. Rac1 as a multifunctional therapeutic target to prevent and combat cancer metastasis. Oncoscience. 2014, 1(8): 513-522
  5. Skvortsova I. Drug Interaction in Ion-Beam Therapy. Chapter 15 in the Book “Ion-Beam Radiotherapy at MedAustron”, 2014; Editors R.Mayer, G.Magrin, T.Schreiner; Druckerei Robitschek; 175-186


  1. Skvortsova I. EDITORIAL Cancer Proteomics. 2013 July


  1. Skvortsova I. EDITORIAL Impact of Intracellular Signaling in Colorectal Cancer (CRC) J Gastroint Dig Syst 2012, 2:4
  2. Skvortsova I. EDITORIAL Signal Transduction and Response to Anti-Cancer Therapy. 2012 Sept


  1. Skvortsov S, Schäfer G, Stasyk T, Fuchsberger C, Bonn GK, Bartsch G, Klocker H, Huber LA. Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J Proteome Res. 2011 Jan 7;10(1):259-68. doi: 10.1021/pr100921j. Epub 2010 Nov 16.
  2. Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M, Hofstetter G, Concin N, Fiegl H, Müller-Holzner E, Marth C, Altevogt P, Zeimet AG.  Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene. 2011 Sep 22;30(38):4038-49.
  3. Haidenberger A, Fromm-Haidenberger S, de Vries A, Popper BA, Steurer M, , Kantner J, Gunsilius E, Lukas P. Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab) for Patients with Non-Hodgkin's Lymphoma: Results of a Prospective Phase I/II Study. Strahlenther Onkol. 2011 May;187(5):300-305.
  4. Skvortsov S, Jimenez CR, Knol JC, Eichberger P, Schiestl B, Debbage P, Lukas P. Radioresistant head and neck squamous cell carcinoma cells: Intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets. Radiother Oncol. 2011 Oct;101(1):177-82


  1. Skvortsova I, Skvortsov S, Raju U, Stasyk T, Riesterer O, Schottdorf EM, Popper BA, Schiestl B, Eichberger P, Debbage P, Neher A, Bonn GK, Huber LA, Milas L, Lukas P. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. Radiother Oncol. 2010 July; 96: 108–115.
  2. Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee K, Altevogt P, Zeimet AG. E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Cancer Res. 2010 Jun 1;70(11):4613-23


  1. Skvortsova I. Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab. Radiother Oncol. 2009 Febr; 90:280–283
  2. Loeffler-Ragg J, Mueller D, Gamerith G, Auer T, Skvortsov S, Sarg B, Skvortsova I, Schmitz KJ, Martin HJ, Krugmann J, Alakus H, Maser E, Menzel J, Hilbe W, Lindner H, Schmid KW, Zwierzina H. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol Cancer Ther. 2009 Jul;8(7):1995-2006


  1. Pircher A, Kähler CM, Skvortsov S, Dlaska M, Kawaguchi G, Schmid T, Gunsilius E, Hilbe W.  Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance. Oncol Rep. 2008 Feb;19(2):345-52.
  2. Morandell S, Stasyk T, Skvortsov S, Ascher S, Huber LA. Quantitative proteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics. 2008 Nov;8(21):4383-401.
  3. Skvortsov S, Sarg B, Lindner H, Lukas P, Hilbe W, Zwierzina H, Skvortsova I. Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor. Proteomics Clin Appl. 2008, 2, 908-914.
  4. Skvortsova I, Skvortsov S, Stasyk S, Raju U, Popper B-A, Schiestl B, von Guggenberg E, Neher A, Bonn GK, Huber LA, Lukas P. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics, 2008 Nov;8(21):4521-33.


  1. Stasyk T, Schiefermeier N, Skvortsov S, Zwierzina H, Peränen J, Bonn GK, Huber LA. Identification of endosomal epidermal growth factor receptor signaling targets by functional organelle proteomics. Mol Cell Proteomics. 2007 May;6(5):908-22.
  2. von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C. (99m)Tc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1209-18.
  3. Skvortsov S, Skvortsova I, Stasyk T, Schiefermeier N, Neher A, Gunkel AR, Bonn GK, Huber LA, Pleiman CM, Zwierzina H. Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines. Mol Cancer Ther. 2007 Jun;6(6):1898-908.
  4. Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, Lukas P, English NM, Sirisoma N, Drewe J, Pervin A, Tseng B, Carlson RO, Pleiman CM. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71


  1. Schmidt S, Rainer J, Riml S, Ploner C, Jesacher S, Achmüller C, Presul E, Skvortsov S, Crazzolara R, Fiegl M, Raivio T, Jänne OA, Geley S, Meister B, Kofler R.Identification of glucocorticoid-response genes in children with acutelymphoblastic leukemia. Blood. 2006 Mar 1;107(5):2061-9.
  2. Sonnweber B, Dlaska M, Skvortsov S, Dirnhofer S, Schmid T, Hilbe W. High predictive value of epidermal growth factorreceptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J Clin Pathol. 2006 Mar;59(3):255-9.
  3. Skvortsova I, Skvortsov S, Popper BA, Haidenberger A, Saurer M, Gunkel AR, Zwierzina H, Lukas P. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms. J Radiat Res (Tokyo). 2006 Jun;47(2):183-96.
  4. Loeffler-Ragg J, Steurer M, Ulmer H, Skvortsov S, Kircher B, Herold M, Zwierzina H, Stauder R. Elevated levels of serum CD44 and E-cadherin predict an unfavourable outcome in myelodysplastic syndromes. Leukemia. 2006 Nov;20(11):2064-7


  1. Skvortsova I, Popper BA, Skvortsov S, Saurer M, Auer T, Moser R, Kamleitner H, Zwierzina H, Lukas P. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (Tokyo). 2005 Jun;46(2):241-8.
  2. Loeffler-Ragg J, Skvortsov S, Sarg B, Skvortsova I, Witsch-Baumgartner M, Mueller D, Lindner H, Zwierzina H. Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. Eur J Cancer. 2005 Oct;41(15):2338-46.
  3. Skvortsov S, Skvortsova I, Sarg B, Loeffler-Ragg J, Lindner H, Lukas P, Tabernero J, Zwierzina H. Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line. Apoptosis. 2005 Oct;10(5):1175-86


  1. Skvortsova I, Skvortsov S, Haidenberger A, DeVries A, Nevinny-Stickel M,Saurer M, Lukas P, Seppi T. Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J Chemother. 2004 Aug;16(4):372-80.
  2. Skvortsov S, Sarg B, Loeffler-Ragg J, Skvortsova I, Lindner H, Werner Ott H, Lukas P, Illmensee K, Zwierzina H. Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Mol Cancer Ther. 2004 Dec;3(12):1551-8


  1. Bernhard D, Skvortsov S, Tinhofer I, Hübl H, Greil R, Csordas A, Kofler R. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ. 2001 Oct;8(10):1014-21
Druckversion | Sitemap